These two biotech stocks could be big winners in the years ahead.
Morning Markets March E-Mini S&P 500 futures (ESH24 ) are down -0.30%, and March Nasdaq 100 E-Mini futures (NQH24 ) are down -0.19%. Stock index futures this morning are mildly lower as higher bond yields...
These two biotechs have been frequent visitors to the buyout-rumor mill and for good reason.
Stocks that are trading heavily or have substantial price changes on Wednesday: Cytokinetics, New York Times rise; Iovance Biotherapeutics fall
Cytokinetics (CYTK) delivered earnings and revenue surprises of -11.29% and 163.60%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Urogen Pharma (URGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.